MXPA05008996A - Inhibidor de homologo de fosfatasa y tensina deletado en el cromosoma diez o abridor de canales de maxi-k. - Google Patents

Inhibidor de homologo de fosfatasa y tensina deletado en el cromosoma diez o abridor de canales de maxi-k.

Info

Publication number
MXPA05008996A
MXPA05008996A MXPA05008996A MXPA05008996A MXPA05008996A MX PA05008996 A MXPA05008996 A MX PA05008996A MX PA05008996 A MXPA05008996 A MX PA05008996A MX PA05008996 A MXPA05008996 A MX PA05008996A MX PA05008996 A MXPA05008996 A MX PA05008996A
Authority
MX
Mexico
Prior art keywords
medicament
opener
pten
maxi
disease
Prior art date
Application number
MXPA05008996A
Other languages
English (en)
Spanish (es)
Inventor
Ki Whan Hong
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MXPA05008996A publication Critical patent/MXPA05008996A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA05008996A 2003-02-25 2004-02-24 Inhibidor de homologo de fosfatasa y tensina deletado en el cromosoma diez o abridor de canales de maxi-k. MXPA05008996A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44943503P 2003-02-25 2003-02-25
US44958903P 2003-02-26 2003-02-26
PCT/JP2004/002146 WO2004075897A1 (en) 2003-02-25 2004-02-24 Pten inhibitor or maxi-k channels opener

Publications (1)

Publication Number Publication Date
MXPA05008996A true MXPA05008996A (es) 2005-10-18

Family

ID=32930512

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008996A MXPA05008996A (es) 2003-02-25 2004-02-24 Inhibidor de homologo de fosfatasa y tensina deletado en el cromosoma diez o abridor de canales de maxi-k.

Country Status (19)

Country Link
US (3) US7825130B2 (enExample)
EP (1) EP1599205B1 (enExample)
JP (3) JP4590397B2 (enExample)
KR (1) KR101031163B1 (enExample)
CN (2) CN1780623B (enExample)
AR (1) AR043379A1 (enExample)
AT (1) ATE345800T1 (enExample)
AU (1) AU2004216340B9 (enExample)
BR (1) BRPI0407832A (enExample)
CA (1) CA2515590C (enExample)
CY (1) CY1106294T1 (enExample)
DE (1) DE602004003348T2 (enExample)
DK (1) DK1599205T3 (enExample)
ES (1) ES2276282T3 (enExample)
MX (1) MXPA05008996A (enExample)
MY (1) MY136863A (enExample)
PT (1) PT1599205E (enExample)
TW (1) TWI323660B (enExample)
WO (1) WO2004075897A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
TWI489983B (zh) * 2007-05-22 2015-07-01 Otsuka Pharma Co Ltd 用於治療阿茲海默症之藥劑
AR067746A1 (es) * 2007-08-02 2009-10-21 Otsuka Pharma Co Ltd Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol
KR101639820B1 (ko) 2008-01-17 2016-07-14 쿠이 류 난소 여포의 체외 성숙 방법
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
US20110189308A1 (en) * 2008-03-17 2011-08-04 Asa Abeliovich Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
CA2724199C (en) * 2008-06-06 2016-07-26 Children's Medical Center Corporation Promoting axon regeneration in the adult cns through control of protein translation
EP2488637B1 (en) * 2009-10-16 2015-12-23 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
CA2854225A1 (en) 2011-11-01 2013-05-10 Children's Medical Center Corporation Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration
KR20150027800A (ko) * 2012-06-15 2015-03-12 고에키 자이단 호징 센탄 이료 신코 자이단 경도 인지 장해의 예방 및/또는 치료제
JP2016040542A (ja) * 2014-08-13 2016-03-24 学校法人金沢医科大学 認知症治療薬または認知症治療薬候補物質のスクリーニング方法
JP2017070404A (ja) * 2015-10-06 2017-04-13 アンディ チャオ トイレ床面の清潔な芳香パッド
KR102181657B1 (ko) * 2016-05-19 2020-11-23 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 치매의 예방 및/또는 치료를 위한 약물
US20230270737A1 (en) * 2020-05-11 2023-08-31 Shimadzu Corporation Therapeutic Agent for Mild Cognitive Impairment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) * 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
JPH0653666B2 (ja) 1990-10-22 1994-07-20 大塚製薬株式会社 ヒトの糖尿病性知覚障害および末梢神経障害の治療剤
JPH0614444A (ja) * 1992-06-25 1994-01-21 Central Japan Railway Co 電力ケーブル接続部の固定装置
JPH06239745A (ja) * 1992-12-24 1994-08-30 Otsuka Pharmaceut Co Ltd 乾癬治療剤
WO1994014444A1 (fr) * 1992-12-24 1994-07-07 Otsuka Pharmaceutical Co., Ltd. Remede contre le psoriasis
JPH0776584A (ja) 1993-09-07 1995-03-20 Otsuka Pharmaceut Co Ltd 内皮細胞障害抑制剤
JP3944257B2 (ja) 1995-12-07 2007-07-11 大塚製薬株式会社 肝実質細胞増殖因子産生増加剤
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
JP2002537231A (ja) * 1998-05-01 2002-11-05 カトラー，ニール，アール 特定の患者群における性的機能障害の治療
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6257985B1 (en) * 1999-10-01 2001-07-10 Rexnord Corporation Global shaft coupling
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
JP4159224B2 (ja) 2000-02-29 2008-10-01 三洋電機株式会社 食器洗浄機
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Also Published As

Publication number Publication date
CA2515590C (en) 2011-09-13
US7825130B2 (en) 2010-11-02
KR20050098960A (ko) 2005-10-12
JP5566482B2 (ja) 2014-08-06
PT1599205E (pt) 2007-01-31
ATE345800T1 (de) 2006-12-15
CN1780623A (zh) 2006-05-31
EP1599205B1 (en) 2006-11-22
US8329731B2 (en) 2012-12-11
AU2004216340B2 (en) 2008-07-31
JP5208172B2 (ja) 2013-06-12
EP1599205A1 (en) 2005-11-30
AU2004216340A1 (en) 2004-09-10
MY136863A (en) 2008-11-28
CA2515590A1 (en) 2004-09-10
HK1148225A1 (zh) 2011-09-02
JP2013082735A (ja) 2013-05-09
US20060154963A1 (en) 2006-07-13
WO2004075897A1 (en) 2004-09-10
US20130065921A1 (en) 2013-03-14
JP2010285456A (ja) 2010-12-24
DE602004003348D1 (de) 2007-01-04
US8653104B2 (en) 2014-02-18
CN101829116A (zh) 2010-09-15
ES2276282T3 (es) 2007-06-16
US20100113515A1 (en) 2010-05-06
KR101031163B1 (ko) 2011-04-27
HK1091409A1 (en) 2007-01-19
TWI323660B (en) 2010-04-21
CN1780623B (zh) 2011-09-14
TW200501954A (en) 2005-01-16
CN101829116B (zh) 2015-11-25
AR043379A1 (es) 2005-07-27
DE602004003348T2 (de) 2007-05-31
CY1106294T1 (el) 2011-10-12
BRPI0407832A (pt) 2006-02-14
DK1599205T3 (da) 2007-03-26
JP2006518732A (ja) 2006-08-17
JP4590397B2 (ja) 2010-12-01
AU2004216340B9 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
MXPA05008996A (es) Inhibidor de homologo de fosfatasa y tensina deletado en el cromosoma diez o abridor de canales de maxi-k.
CA2463552C (en) Treatment of neurodegenerative diseases and cancer of the brain
PL341291A1 (en) 1-substituted derivatives of 1-aminomethyl-ccycloalkanes (gabapentin analogues), their production and application of them in treating neurological disorders
SG159388A1 (en) Antibacterial agents
US6946474B2 (en) Nitrogen-containing compounds and their use as glycine transport inhibitors
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
EP2279727A3 (en) Nanoparticulate aripiprazole formulations
EP2186792A8 (en) 2-(a-hydroxypentyl) benzoate and its preparation and use
GB0225475D0 (en) Therapeutic agents
DE69832268T2 (de) Peptidyl2-amino-1hydroxyalkansulfonsäuren als zysteinprotease-inhibitoren
CA2292968A1 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
TW200745135A (en) Therapeutic agents
CA2500118A1 (en) N-substituted hydromorphones and the use thereof
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
JP2006518732A5 (enExample)
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
TW200635589A (en) Therapeutic agents
WO2006026204A3 (en) Novel gamma-lactams as beta-secretase inhibitors
IL178167A0 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
JP2003534308A (ja) 新規ｍｍｐ−２／ｍｍｐ−９阻害剤
WO2004037769A3 (en) Cycloalkylamides and their therapeutic use as antiepileptic and anticonvulsant
CA2534303A1 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
WO2001007023A3 (en) Azetidine compounds in cns and eye diseases

Legal Events

Date Code Title Description
FG Grant or registration